Summary

Eligibility
for males ages 60-85 (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Dolores M. Shoback, MD (ucsf)
Headshot of Dolores M. Shoback
Dolores M. Shoback

Description

Summary

Details

Keywords

Male Osteoporosis, anabolic therapy, teriparatide, calcimimetic, calcium-sensing receptor, PTH receptor, bone formation, Osteoporosis, Dietary Calcium, Vitamin D, Cholecalciferol, Citric Acid, Sodium Citrate, Calcium, Parathyroid Hormone, Cinacalcet, Hormones, Teriparatide or human parathyroid hormone (PTH) 1-34, Calcium citrate tablet, Vitamin D3, teriparatide (TPTD) + the calcimimetic cinacalcet

Eligibility

Location

  • San Francisco VA Medical Center, San Francisco, CA
    San Francisco California 94121-1563 United States

Lead Scientist at University of California Health

  • Dolores M. Shoback, MD (ucsf)
    Dr. Dolores Shoback cares for patients with a variety of disorders related to the endocrine system, focusing particularly on metabolic bone disease, parathyroid disorders and osteoporosis. She also directs UCSF's physician training program in diabetes, endocrinology and metabolism. Shoback's research interests include metabolic bone disease, the calcium-sensing receptor and parathyroid hormone.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
VA Office of Research and Development
ID
NCT03994172
Phase
Phase 4 Osteoporosis Research Study
Study Type
Interventional
Participants
About 40 people participating
Last Updated